Chen Lingmin, Yang Yi, Fan Jin, Zhang Yonggang, Li Nian
Department of Anesthesiology and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University and The Research Units of West China (2018RU012), Chinese Academy of Medical Sciences, Chengdu, China.
Department of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou, China.
Front Pharmacol. 2021 Sep 16;12:726668. doi: 10.3389/fphar.2021.726668. eCollection 2021.
To investigate the trends of high-impact studies in pharmacology and pharmacy research and to provide evidence for future research in the field of pharmacology and pharmacy. A cross-sectional study was performed to understand the current status of high-impact studies (top 1%) in pharmacology and pharmacy research via InCites tool based on Web of Science Core Collection. VOSViewer software was used to visualize the results. The outcomes included development trends, countries, subject areas, research institutes, collaborative networks, and subject terms. We found 4,273 high-impact (top 1%) studies between 2011 and 2020 in the field of pharmacology and pharmacy. The number of studies increased from 366 in 2011 to 510 in 2020. These studies were mainly distributed in the following Web of Science subject categories: pharmacology and pharmacy ( = 4,188); neurosciences ( = 397); chemistry, multidisciplinary ( = 359); chemistry, medicinal ( = 314); microbiology ( = 301); biotechnology and applied microbiology ( = 280). These studies were cited in 646,855 studies from more than 100 Web of Science subject categories, and studies in pharmacology pharmacy accounted for the largest share of these citations. The top three countries that contributed the highest number of studies were the United States, United Kingdom, and China. The top three institutions that contributed the highest number of studies in the United States were the University of California System, the National Institutes of Health (NIH), and Harvard University. The top research collaborative circle was from universities in the United States. The top international collaborative circle was from universities from the United States, United Kingdom, Australia, and China. The subject-term analysis indicated that cancer was still the top disease, NF-κB was the top signaling pathway, and drug-delivery and nanoparticles were the top methods. The high-impact studies in pharmacology and pharmacy research have grown over time. The United States, the United Kingdom, and China are the top countries that contributed the high-impact studies. Cancer is still the greatest challenge in the field of disease treatment. It calls for more international collaboration in pharmacology and pharmacy research, which will help discover novel drugs.
调查药理学和药学研究中高影响力研究的趋势，并为药理学和药学领域的未来研究提供证据。通过基于Web of Science核心合集的InCites工具进行了一项横断面研究，以了解药理学和药学研究中高影响力研究（前1%）的现状。使用VOSViewer软件对结果进行可视化。结果包括发展趋势、国家、学科领域、研究机构、合作网络和主题词。我们在2011年至2020年期间发现了药理学和药学领域的4273项高影响力（前1%）研究。研究数量从2011年的366项增加到2020年的510项。这些研究主要分布在以下Web of Science学科类别中：药理学和药学（=4188）；神经科学（=397）；多学科化学（=359）；药物化学（=314）；微生物学（=301）；生物技术与应用微生物学（=280）。这些研究被来自100多个Web of Science学科类别的646855项研究所引用，药理学和药学研究在这些引用中占最大份额。贡献研究数量最多的前三个国家是美国、英国和中国。在美国贡献研究数量最多的前三个机构是加利福尼亚大学系统、美国国立卫生研究院（NIH）和哈佛大学。顶级研究合作圈来自美国的大学。顶级国际合作圈来自美国、英国、澳大利亚和中国的大学。主题词分析表明，癌症仍然是头号疾病，NF-κB是头号信号通路，药物递送和纳米颗粒是头号方法。药理学和药学研究中的高影响力研究随着时间的推移而增长。美国、英国和中国是贡献高影响力研究的顶级国家。癌症仍然是疾病治疗领域最大的挑战。这需要药理学和药学研究开展更多国际合作，这将有助于发现新药。
Front Pharmacol. 2021-9-16
Can J Anaesth. 2023-2
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020-3
Indian J Pharmacol. 2016-10
Zhonghua Shao Shang Za Zhi. 2021-3-20
Can J Anaesth. 2023-2
Front Pharmacol. 2022-9-26
Front Psychiatry. 2021-7-22
Front Public Health. 2021
J Affect Disord. 2021-5-15
Front Psychol. 2020-11-30
Eur J Pharmacol. 2021-2-5
Zotero 插件
